Radioprotective Effects of Amifostine, L-Carnitine and Vitamin E in Preventing Early Salivary Gland Injury due to Radioactive Iodine Treatment
-
Published:2019-04-11
Issue:4
Volume:15
Page:395-404
-
ISSN:1573-4056
-
Container-title:Current Medical Imaging Formerly Current Medical Imaging Reviews
-
language:en
-
Short-container-title:CMIR
Author:
Torun Nese1, Muratli Asli2, Serim Burcu Dirlik3, Ergulen Alev4, Altun Gulay Durmus4
Affiliation:
1. Department of Nuclear Medicine, Faculty of Medicine, Baskent University, Ankara, Turkey 2. Department of Pathology, Faculty of Medicine, Baskent University, Ankara, Turkey 3. Department of Nuclear Medicine, Cardiology Institute, İstanbul University, Istanbul, Turkey 4. Department of Nuclear Medicine, Faculty of Medicine, Trakya University, Edirne, Turkey
Abstract
<P>Objective: Standard treatment of differentiated thyroid cancer includes total thyroidectomy
and high-dose Radioactive Iodine Therapy (RIT) for ablation of remnant thyroid tissue.
When administered systemically, RIT can cause radiation-induced damage in non-targeted normal
tissues. The aim of the present study was to compare the protective effects of amifostine (AMI), LCarnitine
(LC), and Vitamin E (EVIT) against high dose radioactive iodine treatment induced Salivary
Gland (SG) damage using SG scintigraphy and histopathological examination.
Methods:
Forty adult guinea pigs were studied. Twenty guinea pigs receive 555-660 MBq
131Iodine intraperitoneally (IP) to ablate the thyroid and impair the parenchymal function of the
SGs. The animals were divided into eight groups as follows: (1) Group 1 (control): 1 mL IP PS
(physiological saline); (2) Group 2: single dose of 200 mg/kg IP AMI one hour prior to 1 mL IP
PS; (3) Group 3: 200 mg/kg IP LC and 1 mL IP PS for 10 days; (4) Group 4: 40 mg/kg intramuscular
(IM) EVITand 1 mL IP PS for 10 days; (5) Group 5: IP RIT after premedication; (6) Group 6:
Single dose of 200 mg/kg IP AMI one hour prior to RIT and IP RIT after premedication; (7) Group
7: IP RIT after premedication and 200 mg/kg IP LC for 10 days starting one day before RIT; and
(8) Group 8: IP RIT after premedication and 40 mg/kg IM EVIT for 10 days starting one day before
RIT. Scintigraphy was performed 1 month after treatment. SGs were examined by light microscopy
and a histopathological scoring system was used to assess the degree of SG damage.
Results:
There were significant differences in the body weight and thyroid hormone levels between
the groups after treatment.
Conclusion:
The individual use of AMI, LC and EVIT for radioprotection yield different levels of
protection against radioactive iodine treatment injury in SGs; however, none of the agents could
provide absolute protection at the doses administered in this experimental model.</P>
Publisher
Bentham Science Publishers Ltd.
Subject
Radiology Nuclear Medicine and imaging
Reference22 articles.
1. Caron NR, Clark OH. Scand J Surg, Well differentiated thyroid cancer.,, 2004, 93,, 261-271, 2. Nostrand DV, , Humana Press,, New Jersey, 2nd edition, Thyroid Cancer A Comprehensive Guide to Clinical Management., 2006,459-485 3. Caglar M, Tuncel M, Alpar R. Clin Nucl Med, Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment.,, 2002, 27,, 767-771, 4. An YS, Yoon JK, Lee SJ, Song HS, Yoon SH, Jo KS. Ann Nucl Med, Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer.,, 2013, 27,, 386-391, 5. Jentzen W, Schneider E, Freudenberg L. Nucl Med Commun, Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.,, 2006, 27,, 669-676,
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|